BBIO: BridgeBio Company Sales Revenue

BridgeBio Pharma, Inc. (BBIO) is creating a closed-loop development cycle for drugs treating genetic pathologies. The company's aggregate sales figures confirm the dynamics of this process, with the value maintained at 0.95. Despite the risks of global instability and sanctions, the launch of commercial sales allows the company to offset research costs, thereby increasing the business's bottom line.

BBIO (BridgeBio Corp) Revenue and Sales Volume history from 07/04/2022 to 11/14/2026

Analytical breakdowns for BridgeBio Pharma, Inc.

- current price and projected stock value:

Share Price BridgeBio Corp|BBIO - Consensus Target

- market capitalization information:

Market Value BridgeBio Pharma|BBIO - Total Company Value

- balance sheet net asset value indicators:

Share Book Value BridgeBio|BBIO - Book Capitalization|Market Value to Book Value bridgebio.com|BBIO - Company Total Assets

- company liabilities and liquidity data:

- net income and valuation multiples indicators:

BBIO - Company Net Income|Expected Net Income BridgeBio Pharma, Inc.|BBIO - P/E Multiple|Market Cap to Projected Earnings bridgebio.com|BBIO - PEG Multiple|Enterprise Value to Operating Income Before Depreciation BridgeBio Pharma|BBIO - Operating profit EBITDA|Net earnings per share for the trailing year BridgeBio|BBIO - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months bridgebio.com|BBIO - Earnings growth in current year|Net earnings per share growth forecast for next year BridgeBio Pharma, Inc.

- company sales and revenue statistics:

BBIO - Revenue and Sales Volume|Company Future Sales BridgeBio Corp|BBIO - Price-to-Revenue Ratio|Market Cap to Future Revenue Ratio BridgeBio Pharma

Comprehensive company analysis:BBIO BridgeBio Corp

BridgeBio Pharma, Inc. (BBIO) operates in a resilient orphan drug niche where revenue depends on regulatory decisions rather than macro cycles. This metric captures the daily inflow of commercial revenue, eliminating reporting gaps. By analyzing the company's aggregated sales, an investor can see the real dynamics of asset monetization. The current calculated value of 0.95 confirms the business's operational status. The stability of this flow determines the market's level of confidence in the issuer's capital.

Key competitors